8-cyclopentyl-6-(6-methoxypyridin-3-yl)-4-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one

ID: ALA3218401

Chembl Id: CHEMBL3218401

PubChem CID: 59258904

Max Phase: Preclinical

Molecular Formula: C20H23N5O2

Molecular Weight: 365.44

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CNc1nc(C)c2cc(-c3ccc(OC)nc3)c(=O)n(C3CCCC3)c2n1

Standard InChI:  InChI=1S/C20H23N5O2/c1-12-15-10-16(13-8-9-17(27-3)22-11-13)19(26)25(14-6-4-5-7-14)18(15)24-20(21-2)23-12/h8-11,14H,4-7H2,1-3H3,(H,21,23,24)

Standard InChI Key:  KBIZOMLODGCSPM-UHFFFAOYSA-N

Associated Targets(Human)

MTOR Tclin Serine/threonine-protein kinase mTOR (13850 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PIK3CA Tclin PI3-kinase p110-alpha subunit (12269 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Pik3ca PI3-kinase p110-alpha subunit (153 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 365.44Molecular Weight (Monoisotopic): 365.1852AlogP: 3.33#Rotatable Bonds: 4
Polar Surface Area: 81.93Molecular Species: NEUTRALHBA: 7HBD: 1
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 3.54CX LogP: 2.66CX LogD: 2.66
Aromatic Rings: 3Heavy Atoms: 27QED Weighted: 0.76Np Likeness Score: -1.11

References

1. Cheng H, Bagrodia S, Bailey S, Edwards M, Hoffman J, Hu Q, Kania R, Knighton DR, Marx MA, Ninkovic S, Sun S, Zhang E.  (2010)  Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design,  (2): [10.1039/C0MD00072H]
2.  (2014)  4-methylpyridopyrimidinone compounds,